Objective: To evaluate the association between the tumor necrosis factor superfamily member 4 (TNFSF4) gene polymorphisms and common cardiovascular and cerebrovascular diseases.
Methods: A literature-based search was operated through database including PubMed, EMBASE, Cochrane Library, CNKI and WanFang data. Crude odds ratios (ORs) and 95% confidence intervals (CI) were calculated to estimate the strength of the association between TNFSF4 polymorphisms (rs3850641 and rs17568) and the risk of coronary heart disease and stroke.
Results: 11 eligible studies were included in this meta-analysis. It was showed that G allele was not associated with CHD and stroke, compared with A allele (rs3850641: OR 1.02, 95%CI.: 0.89, 1.17; rs17568: OR 1.09, 95%CI.: 0.89, 1.33). Genotypic analysis demonstrated that there was no significantly association between the risk of CHD and stroke and rs3850641 (homozygous comparison (GG vs. AA): OR 1.05, 95%CI.: 0.74, 1.50; heterozygous comparison (GA vs. AA): OR 1.00, 95%CI.: 0.88, 1.13; recessive model (GG vs. GA + AA): OR 1.04, 95%CI.: 0.76, 1.43; dominant model (GG + GA vs. AA): OR 1.01, 95%CI.: 0.88, 1.17). Similarly, no susceptibility between CHD and stroke and rs17568 polymorphism was uncovered (GG vs. AA: OR 1.04, 95%CI.: 0.74, 1.46; GA vs. AA: OR 1.07, 95%CI.: 0.62, 1.83; GG + GA vs. AA: OR 1.13, 95%CI.: 0.82, 1.56; GG vs. GA + AA: OR 1.01, 95%CI.: 0.74-1.39).
Conclusions: The present study demonstrated that there is no significant relationship between TNFSF4 gene polymorphism and cerebrovascular and cardiovascular diseases.